



*Collaboration. Acceleration. Results.*

**Media Contact:**  
Carol Menaker  
[carol@myelinrepair.org](mailto:carol@myelinrepair.org)  
408-871-2410

## **Fast Company Names the MRF Among Top 10 Biotechs for Innovation**

**Saratoga, CA, February 16, 2011** – The Myelin Repair Foundation (MRF) was named #9 in the **Top 10** list of biotech companies in ***Fast Company's 2011 ranking of most innovative companies***. According to the magazine, the MRF was selected for its “unorthodox, highly collaborative approach to drug development.”

In its March 2011 issue, in addition to its annual recognition of Top 50 companies, for the first time, *Fast Company* ranked the top 10 most innovative companies in 26 categories. All honorees were selected from thousands of businesses across the globe.

“Innovation has never been more important to our economy and our future,” said *Fast Company* editor Robert Safian. “These companies embody what unleashing human potential can accomplish.”

Though the MRF shares the **Top 10 honors** with such companies as Amgen, Omeros, Amyris and others, it is the only non-profit organization represented on the list. The MRF was also among ***Fast Company's Fast 50*** in March of 2007.

“We are honored to be included among so many outstanding companies,” says MRF President and founder Scott Johnson. “And to receive this recognition for the second time in four years is testimony to our staying power, and to our commitment to innovation and results. We remain wholly committed to accelerating the process of bringing new medicines to market and delivering a myelin repair treatment to MS patients in an unprecedented time frame.”

*Fast Company's Most Innovative Companies* issue (March 2011) available online at [www.fastcompany.com/MIC](http://www.fastcompany.com/MIC).

###

### **About the Myelin Repair Foundation**

The Myelin Repair Foundation (MRF) -<http://www.myelinrepair.org> -is a Northern California-based, non-profit organization focused on demonstrating a new model for medical research and drug development that shortens the time to market for treatments and cures for all diseases. Their proof of concept project is on developing myelin repair treatments for multiple sclerosis.